SCM
CLDX icon

Suffolk Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Suffolk Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,020
Closed -$1.46M – 140
2016
Q3 		$1.46M Sell
24,020
-7,633
-24% -$475K 0.2% 96
2016
Q2 		$2.08M Buy
31,653
+2,578
+9% +$164K 0.27% 115
2016
Q1 		$1.65M Buy
29,075
+17,927
+161% +$2.02M 0.22% 128
2015
Q4 		$2.62M Buy
11,148
+2,727
+32% +$594K 0.33% 90
2015
Q3 		$1.33M Buy
8,421
+1,856
+28% +$525K 0.18% 125
2015
Q2 		$2.48M Buy
6,565
+1,361
+26% +$540K 0.3% 109
2015
Q1 		$2.18M Sell
5,204
-6,033
-54% -$2.16M 0.26% 118
2014
Q4 		$3.08M Buy
11,237
+920
+9% +$229K 0.37% 77
2014
Q3 		$2.01M Buy
10,317
+1,206
+13% +$263K 0.25% 116
2014
Q2 		$2.23M Buy
9,111
+1,534
+20% +$346K 0.27% 115
2014
Q1 		$2.01M Sell
7,577
-167
-2% -$63.9K 0.25% 121
2013
Q4 		$2.81M Buy
7,744
+1,787
+30% +$688K 0.35% 95
2013
Q3 		$3.17M Sell
5,957
-2,754
-32% -$944K 0.43% 71
2013
Q2 		$2.04M Buy
+8,711
New +$1.72M 0.29% 117

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Suffolk Capital Management's CLDX Position: Q4 2016 in Review

Suffolk Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2016, closing a stake of 24,020 shares — an estimated $1.46M sold.

Suffolk Capital Management first reported a position in CLDX in Q2 2013 and held it in 14 quarters. The position peaked at $3.17M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • Suffolk Capital Management reported no remaining Celldex Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Suffolk Capital Management sold 24,020 Celldex Therapeutics shares in Q4 2016, an estimated $1.46M.
  • Suffolk Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 14 quarters.
  • Suffolk Capital Management's Celldex Therapeutics position peaked at $3.17M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on Suffolk Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.